Levine, A. J. & Oren, M. The primary 30 years of p53: rising ever extra complicated. Nat. Rev. Most cancers 9, 749–758 (2009).
Shaw, P. H. The function of p53 in cell cycle regulation. Pathol. Res. Pract. 192, 669–675 (1996).
Vousden, Ok. H. & Lane, D. P. p53 in well being and illness. Nat. Rev. Mol. Cell Biol. 8, 275–283 (2007).
Vousden, Ok. H. & Ryan, Ok. M. p53 and metabolism. Nat. Rev. Most cancers 9, 691–700 (2009).
The Most cancers Genome Atlas Analysis Community Built-in genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).
Olivier, M., Hollstein, M. & Hainaut, P. TP53 mutations in human cancers: origins, penalties, and scientific use. Chilly Spring Harb. Perspect. Biol. 2, a001008 (2010).
Bertheau, P. et al. p53 in breast most cancers subtypes and new insights into response to chemotherapy. Breast 22, S27–S29 (2013).
Freed-Pastor, W. A. & Prives, C. Mutant p53: one title, many proteins. Genes Dev. 26, 1268–1286 (2012).
Muller, P. A. & Vousden, Ok. H. p53 mutations in most cancers. Nat. Cell Biol. 15, 2–8 (2013).
Yue, X. et al. Mutant p53 in most cancers: accumulation, gain-of-function, and remedy. J. Mol. Biol. 429, 1595–1606 (2017).
Lukashchuk, N. & Vousden, Ok. H. Ubiquitination and degradation of mutant p53. Mol. Cell Biol. 27, 8284–8295 (2007).
Schulz-Heddergott, R. et al. Therapeutic ablation of gain-of-function mutant p53 in colorectal most cancers inhibits Stat3-mediated tumor development and invasion. Most cancers Cell 34, 298–314 (2018).
Zhang, C. et al. Achieve-of-function mutant p53 in most cancers development and remedy. J. Mol. Cell Biol. 12, 674–687 (2020).
Bykov, V. J. N., Eriksson, S. E., Bianchi, J. & Wiman, Ok. G. Concentrating on mutant p53 for environment friendly most cancers remedy. Nat. Rev. Most cancers 18, 89–102 (2018).
Parrales, A. & Iwakuma, T. Concentrating on oncogenic mutant p53 for most cancers remedy. Entrance. Oncol. 5, 288 (2015).
Zhang, Y. J. et al. Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8. Biomaterials 271, 120720 (2021).
Qian, J. et al. Enhancing chemotherapy of p53‐mutated most cancers by ubiquitination‐dependent proteasomal degradation of mutant p53 proteins by engineered ZnFe‐4 nanoparticles. Adv. Funct. Mater. 30, 2001994 (2020).
Kocaturk, N. M. & Gozuacik, D. Crosstalk between mammalian autophagy and the ubiquitin–proteasome system. Entrance. Cell Dev. Biol. 6, 128 (2018).
Jing, M. et al. Photoresponsive PAMAM-assembled nanocarrier loaded with autophagy inhibitor for synergistic most cancers remedy. Small 17, e2102295 (2021).
Lee, C. W. et al. Selective autophagy degrades nuclear pore complexes. Nat. Cell Biol. 22, 159–166 (2020).
Zhang, Y. et al. Harnessing copper–palladium alloy tetrapod nanoparticle-induced pro-survival autophagy for optimized photothermal remedy of drug-resistant most cancers. Nat. Commun. 9, 4236 (2018).
Khaminets, A., Behl, C. & Dikic, I. Ubiquitin-dependent and unbiased alerts in selective autophagy. Developments Cell Biol. 26, 6–16 (2016).
Kirkin, V. & Rogov, V. V. A variety of selective autophagy receptors determines the specificity of the autophagy pathway. Mol. Cell 76, 268–285 (2019).
Shaid, S., Brandts, C. H., Serve, H. & Dikic, I. Ubiquitination and selective autophagy. Cell Loss of life Differ. 20, 21–30 (2013).
Sarraf, S. A. et al. Lack of TAX1BP1-directed autophagy leads to protein mixture accumulation within the mind. Mol. Cell 80, 779–795 (2020).
Jo, C. et al. Nrf2 reduces ranges of phosphorylated tau protein by inducing autophagy adaptor protein NDP52. Nat. Commun. 5, 3496 (2014).
Pankiv, S. et al. p62/SQSTM1 binds on to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J. Biol. Chem. 282, 24131–24145 (2007).
Guida, E. et al. Peptide aptamers concentrating on mutant p53 induce apoptosis in tumor cells. Most cancers Res. 68, 6550–6558 (2008).
Man, N., Chen, Y., Zheng, F., Zhou, W. & Wen, L. P. Induction of real autophagy by cationic lipids in mammalian cells. Autophagy 6, 449–454 (2010).
Roberts, R. et al. Autophagy and formation of tubulovesicular autophagosomes present a barrier in opposition to nonviral gene supply. Autophagy 9, 667–682 (2013).
Li, M. et al. Mono- versus polyubiquitination: differential management of p53 destiny by Mdm2. Science 302, 1972–1975 (2003).
Li, M., Luo, J., Brooks, C. L. & Gu, W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol. Chem. 277, 50607–50611 (2002).
Maeda, H., Nakamura, H. & Fang, J. The EPR impact for macromolecular drug supply to stable tumors: enchancment of tumor uptake, decreasing of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 65, 71–79 (2013).
Peer, D. et al. Nanocarriers as an rising platform for most cancers remedy. Nat. Nanotechnol. 2, 751–760 (2007).
Alexandrova, E. M. et al. Enhancing survival by exploiting tumour dependence on stabilized mutant p53 for therapy. Nature 523, 352–356 (2015).
Ghosh, M. et al. Mutant p53 suppresses innate immune signaling to advertise tumorigenesis. Most cancers Cell 39, 494–508 (2021).
Baslan, T. et al. Ordered and deterministic most cancers genome evolution after p53 loss. Nature 608, 795–802 (2022).
Parrales, A. et al. DNAJA1 controls the destiny of misfolded mutant p53 by the mevalonate pathway. Nat. Cell Biol. 18, 1233–1243 (2016).
Proia, D. A. & Bates, R. C. Ganetespib and HSP90: translating preclinical hypotheses into scientific promise. Most cancers Res. 74, 1294–1300 (2014).
Padmanabhan, A. et al. USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian most cancers cells. Nat. Commun. 9, 1270 (2018).
Garufi, A. et al. Degradation of mutant p53H175 protein by Zn(II) by autophagy. Cell Loss of life Dis. 5, e1271 (2014).
Li, Z. et al. Allele-selective decreasing of mutant HTT protein by HTT–LC3 linker compounds. Nature 575, 203–209 (2019).
Winter, G. E. et al. Phthalimide conjugation as a technique for in vivo goal protein degradation. Science 348, 1376–1381 (2015).
Li, H. J. et al. Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy. Proc. Natl Acad. Sci. USA 113, 4164–4169 (2016).
